06.11.2019 07:45:00
|
Agfa-Gevaert comments on its achievements in the third quarter of 2019 - Regulated information – November 6, 2019 - 7:45 a.m. CET
?
Milestones in the transformation process
· Auction process for part of the activities of Agfa HealthCare launched in third quarter
· Implementation of offset alliance with Lucky HuaGuang Graphics is running according to plan
Financial results
· Top line growth based on good performances of most of the growth engines and the effects of the offset alliance
· Adjusted EBIT at 24 million Euro (including IFRS 16)
· Net result at minus 4 million Euro (including IFRS 16)
· Net debt decrease versus previous quarter due to working capital improvement
Mortsel (Belgium), November 6, 2019 - Agfa-Gevaert today commented on its achievements in the third quarter of 2019.
MILESTONES IN THE AGFA-GEVAERT GROUP’S TRANSFORMATION PROCESS
"In the third quarter, we launched the auction process for the sale of part of the IT activities of Agfa HealthCare. It is progressing according to plan and we hope to finish this auction process by the end of the year.
The implementation of the offset alliance with Lucky HuaGuang Graphics is also running as expected. We continued to expand the common sales platform into more regions within China. We started to recognize sales from the alliance in our top line in the second quarter and this accelerated in the past few months. This top line impact is expected to continue to grow gradually in the quarters to come,” said Christian Reinaudo, President and CEO of the Agfa-Gevaert Group.
FINANCIAL RESULTS
"For the second quarter in a row, we are able to report top line growth. Most of our growth engines performed well and the hardcopy range continued to benefit from the reorganization of the Chinese distribution channels. Within the HealthCare IT division especially the HealthCare Information Solutions business performed well. As announced in August, the termination of the reseller activities related to inkjet media in the USA impacted the top line of the Digital Print & Chemicals division.
The program we initiated to improve our trade working capital is starting to bear fruit. In the third quarter, the working capital improvements resulted in a stronger cash generation and a decline in net financial debt,” said Christian Reinaudo, President and CEO of the Agfa-Gevaert Group.
Statement on IFRS 16 and 2018 restated profit and loss numbers
Several factors influence the way the Agfa-Gevaert Group reports its financial results as from the first quarter of 2019.
The activities of the Agfa-Gevaert Group have been regrouped into four divisions. To allow for a more accurate assessment of the business performances, some costs of corporate functions at Group level (e.g. Investor Relations, Corporate Finance, Internal Audit, the newly created Innovation Office,…) are no longer attributed to the business divisions. For Q3 2019, these costs amounted to 3.7 million Euro (Q3 2018: 3.7 million Euro). These costs are now grouped under Corporate Services. To allow comparison, the Q3 2018 profit and loss numbers have been restated.
As from 2019, the Agfa-Gevaert Group has adopted the IFRS 16 accounting rules. However, to allow correct comparison with Q3 2018, the tables below present the Q3 2019 profit and loss numbers excluding the impact of IFRS 16.
Agfa-Gevaert Group – Q3 2019
in million Euro |
Q3 2019 (excl. IFRS 16) |
Q3 2018 Restated (excl. IFRS 16) |
% change (excl. FX effects) |
Revenue | 553 | 539 | 2.6% (1.1%) |
Gross profit (*) | 171 | 171 | -0.1% |
% of revenue | 31.0% | 31.8% | |
Adjusted EBITDA (*) | 38** | 35 | 9.1% |
% of revenue | 6.9% | 6.5% | |
Adjusted EBIT (*) | 24** | 21 | 11.1% |
% of revenue | 4.3% | 4.0% | |
Result from operating activities | 17 | 6 | 172.8% |
(*) before restructuring and non-recurring items
(**) Q3 2019 Adjusted EBITDA including IFRS 16: 48 million Euro
Q3 2019 Adjusted EBIT including IFRS 16: 24 million Euro
Continuing the positive evolution of the first half of the year, the Agfa-Gevaert Group’s top line grew by 2.6% (1.1% excluding exchange rate effects) in the third quarter of 2019. Most growth engines, as well as the hardcopy product line, contributed to the top line growth. The Digital Print & Chemicals division’s top line was impacted by the decision to discontinue the reseller activities related to inkjet media in the USA, which was announced in August. Excluding the effect of this decision, the Group’s revenue growth would amount to 5.7%.
The Group’s gross profit margin decreased from 31.8% of revenue in the third quarter of 2018 to 31.0%. The main reasons were adverse product and regional mix effects, the negative impact of high aluminum costs, as well as the dilutive effect related to the consolidation of the sales coming from the alliance with Lucky HuaGuang Graphics.
Selling and General Administration expenses decreased from 115 million Euro (21.4% of revenue) in the third quarter of 2018 to 111 million Euro (20.1% of revenue).
R&D expenses amounted to 37 million Euro (6.6% of revenue), versus 32 million Euro (6.0% of revenue) in the third quarter of 2018.
Excluding the effects of IFRS 16, adjusted EBITDA improved from 6.5% of revenue in the third quarter of 2018 to 6.9%. Adjusted EBIT reached 4.3% of revenue, versus 4.0% in the third quarter of 2018.
Restructuring and non-recurring items resulted in an expense of 7 million Euro, versus an expense of 15 million Euro in the third quarter of 2018, when the impact of costs related to the Group’s transformation efforts were more significant.
The net finance costs (including IFRS 16) amounted to 11 million Euro.
Income tax expenses (including IFRS 16) amounted to 10 million Euro, versus 0 million Euro in 2018 and included some effects of the carve-out of HealthCare IT.
As a result of the elements mentioned above, the Agfa-Gevaert Group posted a net loss of minus 4 million Euro (including IFRS 16).
Financial position and cash flow (including IFRS 16)
- At the end of September 2019, total assets were 2,399 million Euro (comprising right-of-use assets compliant with the new accounting standard on leases: 112 million Euro at the end of September 2019), compared to 2,367 million Euro at the end of 2018.
- Trade working capital moved from 653 million Euro (29% of sales) at the end of 2018 to 633 million Euro (28% of sales) at the end of September 2019.
- Net financial debt amounted to 276 million Euro (or 161 million Euro excluding the impact of IFRS 16), versus 144 million Euro at the end of 2018.
- Net cash from operating activities amounted to 50 million Euro.
Offset Solutions – Q3 2019
in million Euro |
Q3 2019 (excl. IFRS 16) |
Q3 2018 Restated (excl. IFRS 16) |
% change (excl. FX effects) |
Revenue | 212 | 204 | 3.6% (1.9%) |
Adjusted EBITDA (*) | 3.4** | 5.9 | -42.7% |
% of revenue | 1.6% | 2.9% | |
Adjusted EBIT (*) | (0.8)** | 0.6 | |
% of revenue | (0.4)% | 0.3% |
(*) before restructuring and non-recurring items
(**) Q3 2019 Adjusted EBITDA including IFRS 16: 6.3 million Euro
Q3 2019 Adjusted EBIT including IFRS 16: minus 0.7 million Euro
As the alliance with Lucky HuaGuang Graphics is coming up to speed, the Offset Solutions division was able to post a 3.6% top line growth (1.9% excluding currency effects) compared to the third quarter of 2018. It is expected that the effects of the alliance will become increasingly visible in the coming quarters.
The Offset Solutions division is active in structurally declining markets. The offset industry is marked by the strong decline in demand for analog prepress technology and decreasing newspaper and commercial print volumes. The division also continues to face price pressure, caused by intense competition.
The Offset Solutions division’s gross profit margin decreased from 24.6% of revenue in the third quarter of 2018 to 20.7%. Half of the decrease was due to the dilutive effect related to the consolidation of the sales coming from the alliance with Lucky HuaGuang Graphics. In addition, adverse product and regional mix effects, increased idle time due to overcapacity and high aluminum costs also impacted the gross profit margin. Excluding the effects of IFRS 16, adjusted EBITDA amounted to 3.4 million Euro (1.6% of revenue), versus 5.9 million Euro (2.9% of revenue) in the third quarter of 2018 and adjusted EBIT amounted to minus 0.8 million Euro (minus 0.4% of revenue), versus 0.6 million Euro (0.3% of revenue).
In the third quarter, HP Indigo and Agfa announced a unique variable design security solution for brand protection and security printing. HP Indigo Secure Studio Powered by Agfa creates unique graphic designs with endless variations.
Digital Print & Chemicals – Q3 2019
in million Euro |
Q3 2019 (excl. IFRS 16) |
Q3 2018 Restated (excl. IFRS 16) |
% change (excl. FX effects) |
Revenue | 85 | 98 | -13.0% (-14.0%) |
Adjusted EBITDA (*) | 2.8** | 7.6 | -63.1% |
% of revenue | 3.3% | 7.8% | |
Adjusted EBIT (*) | 1.1** | 6.2 | -82.6% |
% of revenue | 1.3% | 6.3% |
(*) before restructuring and non-recurring items
(**) Q3 2019 Adjusted EBITDA including IFRS 16: 4.0 million Euro
Q3 2019 Adjusted EBIT including IFRS 16: 1.1 million Euro
Mainly as a result of the discontinuation of the reseller activities related to inkjet media in the USA, the top line of the Digital Print & Chemicals division decreased by 13.0% (14.0% excluding currency effects) compared to the third quarter of 2018. In inkjet, the ink product ranges performed well, whereas equipment sales were weaker following a strong second quarter.
In the Industrial Films and Foils segment, the Synaps Synthetic Paper range and the Security range performed well. The Electronic Print segment’s Orgacon Electronic Materials range also reported good sales figures.
The division’s gross profit margin decreased from 27.1% of revenue in the third quarter of 2018 to 26.8%. Excluding the effects of IFRS 16, the division’s adjusted EBITDA reached 2.8 million Euro (3.3% of revenue), versus 7.6 million Euro (7.8% of revenue) in the third quarter of 2018. Adjusted EBIT amounted to 1.1 million Euro (1.3% of revenue), versus 6.2 million Euro (6.3% of revenue). With the main impact of the strategic alliance for UV digital packaging inks with Siegwerk Druckfarben coming to an end, the third quarter 2019 adjusted EBITDA margin was negatively influenced. Excluding this effect, the adjusted EBITDA margin would have remained stable.
Early October, Agfa announced that its Jeti Mira 2732 HS LM LED printing system was named as the winner of the 2019 Product of the Year award by the Specialty Graphic Imaging Association (SGIA) in the UV/Latex Flatbed ($200,000-$500,000) category.
Radiology Solutions – Q3 2019
in million Euro |
Q3 2019 (excl. IFRS 16) |
Q3 2018 Restated (excl. IFRS 16) |
% change (excl. FX effects) |
Revenue | 132 | 118 | 11.8% (9.8%) |
Adjusted EBITDA (*) | 19.7** | 14.5 | 35.2% |
% of revenue | 14.9% | 12.4% | |
Adjusted EBIT (*) | 15.6** | 11.2 | 38.8% |
% of revenue | 11.9% | 9.5% |
(*) before restructuring and non-recurring items
(**) Q3 2019 Adjusted EBITDA including IFRS 16: 22.0 million Euro
Q3 2019 Adjusted EBIT including IFRS 16: 15.8 million Euro
The Radiology Solutions division’s revenue increased by 11.8% compared to the third quarter of 2018 based on double-digit growth for both the hardcopy business and the Direct Radiography solutions range. The hardcopy business continued to benefit from the effects of the reorganization of the distribution channels in China. The top line growth of the innovative Direct Radiography solutions range was partly based on increased service revenues.
Due to regional and product/mix effects, the division’s gross profit margin decreased from 35.8% of revenue in the third quarter of 2018 to 34.9%. Excluding the effects of IFRS 16, adjusted EBITDA increased from 14.5 million Euro (12.4% of revenue) in the third quarter of 2018 to 19.7 million Euro (14.9% of revenue). Adjusted EBIT reached 15.6 million Euro (11.9% of revenue), versus 11.2 million Euro (9.5% of revenue) in the previous year.
HealthCare IT – Q3 2019
in million Euro |
Q3 2019 (excl. IFRS 16) |
Q3 2018 Restated (excl. IFRS 16) |
% change (excl. FX effects) |
Revenue | 125 | 119 | 5.0% (3.7%) |
Adjusted EBITDA (*) | 16.0** | 10.6 | 50.4% |
% of revenue | 12.8% | 8.9% | |
Adjusted EBIT (*) | 11.7** | 7.1 | 64.6% |
% of revenue | 9.3% | 6.0% |
(*) before restructuring and non-recurring items
(**) Q3 2019 Adjusted EBITDA including IFRS 16: 19.9 million Euro
Q3 2019 Adjusted EBIT including IFRS 16: 12.0 million Euro
The HealthCare IT division posted substantial top line growth, based on the good performance of the HealthCare Information Solutions business especially.
Like in the previous quarters, the HealthCare Information Solutions business again recorded solid top line growth, confirming its leading position in the German speaking countries of Europe and in France.
The gross profit margin improved from 44.2% of revenue in the third quarter of 2018 to 47.1%. Significant service efficiency improvements, strong software sales and the decision to wind down the Imaging IT Solutions from certain less sustainable markets had a positive effect on profitability. Excluding the effects of IFRS 16, adjusted EBITDA increased from 10.6 million Euro (8.9% of revenue) in the third quarter of 2018 to 16.0 million Euro (12.8% of revenue). Adjusted EBIT reached 11.7 million Euro (9.3% of revenue), versus 7.1 million Euro (6.0% of revenue) in the previous year.
Corporate Services – Q3 2019
in million Euro |
Q3 2019 (excl. IFRS 16) |
Q3 2018 Restated (excl. IFRS 16) |
Adjusted EBITDA (*) | (3.7)** | (3.7) |
Adjusted EBIT (*) | (3.7)** | (3.7) |
(*) before restructuring and non-recurring items
(**) Q3 2019 Adjusted EBITDA including IFRS 16: minus 3.7 million Euro
Q3 2019 Adjusted EBIT including IFRS 16: minus 3.7 million Euro
To allow for a more accurate assessment of the business performances, costs of corporate functions at Group level (e.g. Investor Relations, Corporate Finance, Internal Audit, the newly created Innovation Office,…) are grouped under Corporate Services.
Results after nine months
Agfa-Gevaert Group – year to date
in million Euro |
9M 2019 (excl. IFRS 16) |
9M 2018 Restated (excl. IFRS 16) |
% change (excl. FX effects |
Revenue | 1,668 | 1,647 | 1.3% (-0.2%) |
Gross profit (*) | 542 | 529 | 2.3% |
% of revenue | 32.5% | 32.1% | |
Adjusted EBITDA (*) | 127** | 121 | 4.8% |
% of revenue | 7.6% | 7.3% | |
Adjusted EBIT (*) | 85** | 81 | 4.6% |
% of revenue | 5.1% | 4.9% | |
Result from operating activities | 63 | 52 | 19.6% |
(*) before restructuring and non-recurring items
(**) 9M 2019 Adjusted EBITDA including IFRS 16: 157 million Euro
9M 2019 Adjusted EBIT including IFRS 16: 86 million Euro
Offset Solutions – year to date
in million Euro |
9M 2019 (excl. IFRS 16) |
9M 2018 Restated (excl. IFRS 16) |
% change (excl. FX effects) |
Revenue | 617 | 632 | -2.2% (-4.0%) |
Adjusted EBITDA (*) | 13.0** | 30.8 | -58.0% |
% of revenue | 2.1% | 4.9% | |
Adjusted EBIT (*) | (0.7)** | 14.7 | |
% of revenue | (0.1)% | 2.3% |
(*) before restructuring and non-recurring items
(**) 9M 2019 Adjusted EBITDA including IFRS 16: 21.5 million Euro
9M 2019 Adjusted EBIT including IFRS 16: minus 0.5 million Euro
Digital Print & Chemicals – year to date
in million Euro |
9M 2019 (excl. IFRS 16) |
9M 2018 Restated (excl. IFRS 16) |
% change (excl. FX effects) |
Revenue | 294 | 292 | 0.6% (-1.3%) |
Adjusted EBITDA (*) | 23.7** | 21.5 | 10.4% |
% of revenue | 8.1% | 7.4% | |
Adjusted EBIT (*) | 18.5** | 17.1 | 7.9% |
% of revenue | 6.3% | 5.9% |
(*) before restructuring and non-recurring items
(**) 9M 2019 Adjusted EBITDA including IFRS 16: 27.2 million Euro
9M 2019 Adjusted EBIT including IFRS 16: 18.6 million Euro
Radiology Solutions – year to date
in million Euro |
9M 2019 (excl. IFRS 16) |
9M 2018 Restated (excl. IFRS 16) |
% change (excl. FX effects) |
Revenue | 383 | 364 | 5.2% (4.7%) |
Adjusted EBITDA (*) | 56.8** | 47.3 | 20.2% |
% of revenue | 14.9% | 13.0% | |
Adjusted EBIT (*) | 44.7** | 38.0 | 17.5% |
% of revenue | 11.7% | 10.5% |
(*) before restructuring and non-recurring items
(**) 9M 2019 Adjusted EBITDA including IFRS 16: 63.4 million Euro
9M 2019 Adjusted EBIT including IFRS 16: 44.9 million Euro
HealthCare IT – year to date
in million Euro |
9M 2019 (excl. IFRS 16) |
9M 2018 Restated (excl. IFRS 16) |
% change (excl. FX effects) |
Revenue | 374 | 360 | 3.9% (2.3%) |
Adjusted EBITDA (*) | 45.3** | 32.3 | 40.1% |
% of revenue | 12.1% | 9.0% | |
Adjusted EBIT (*) | 34.5** | 22.1 | 56.0% |
% of revenue | 9.2% | 6.1% |
(*) before restructuring and non-recurring items
(**) 9M 2019 Adjusted EBITDA including IFRS 16: 57.1 million Euro
9M 2019 Adjusted EBIT including IFRS 16: 35.3 million Euro
Corporate Services – year to date
in million Euro |
9M 2019 (excl. IFRS 16) |
9M 2018 Restated (excl. IFRS 16) |
Adjusted EBITDA (*) | (12.1)** | (10.9) |
Adjusted EBIT (*) | (12.2)** | (10.9) |
(*) before restructuring and non-recurring items
(**) 9M 2019 Adjusted EBITDA including IFRS 16: minus 12.1 million Euro
9M 2019 Adjusted EBIT including IFRS 16: minus 12.2 million Euro
End of message
Management Certification of Financial Statements and Quarterly Report
This statement is made in order to comply with new European transparency regulation enforced by the Belgian Royal Decree of 14 November 2007 and in effect as of 2008.
"The Board of Directors and the Executive Committee of Agfa-Gevaert NV, represented by Mr. Klaus Röhrig, Chairman of the Board of Directors, Mr. Christian Reinaudo, President and CEO, and Mr. Dirk De Man, CFO, jointly certify that, to the best of their knowledge, the consolidated financial statements included in the report and based on the relevant accounting standards, fairly present in all material respects the financial condition and results of Agfa-Gevaert NV, including its consolidated subsidiaries. Based on our knowledge, the report includes all information that is required to be included in such document and does not omit to state all necessary material facts.”
Statement of risk
This statement is made in order to comply with new European transparency regulation enforced by the Belgian Royal Decree of 14 November 2007 and in effect as of 2008.
"As with any company, Agfa is continually confronted with – but not exclusively - a number of market and competition risks or more specific risks related to the cost of raw materials, product liability, environmental matters, proprietary technology or litigation."
Key risk management data is provided in the annual report available on www.agfa.com.
Contact:
Viviane Dictus
Director Corporate Communication
Septestraat 27
2640 Mortsel - Belgium
T +32 (0) 3 444 71 24
E viviane.dictus@agfa.com
Johan Jacobs
Corporate Press Relations Manager
T +32 (0)3/444 80 15
E johan.jacobs@agfa.com
The full press release and financial information is also available on the company's website: www.agfa.com
Consolidated Statement of Profit or Loss (in million Euro)
Unaudited, consolidated figures following IFRS accounting policies.
Q3 2019 |
Q3 2018 |
9M 2019 |
9M 2018 | |
Revenue | 553 | 539 | 1,668 | 1,647 |
Cost of sales | (382) | (368) | (1,127) | (1,118) |
Gross profit | 172 | 171 | 541 | 529 |
Selling expenses | (72) | (79) | (230) | (240) |
Administrative expenses | (42) | (42) | (129) | (128) |
R&D expenses | (36) | (32) | (108) | (105) |
Net impairment loss on trade and other receivables, including contract assets | (1) | (2) | (4) | (3) |
Other operating income | 17 | 11 | 42 | 46 |
Other operating expenses | (19) | (20) | (48) | (46) |
Results from operating activities | 18 | 6 | 64 | 53 |
Interest income (expense) - net | (2) | (2) | (6) | (5) |
Interest income | - | 1 | 1 | 1 |
Interest expense | (2) | (3) | (8) | (7) |
Other finance income (expense) - net | (9) | (9) | (25) | (26) |
Other finance income | 1 | 2 | 5 | 2 |
Other finance expense | (10) | (11) | (29) | (27) |
Net finance costs | (11) | (11) | (31) | (31) |
Share of profit of associates, net of tax | - | - | (1) | (1) |
Profit (loss) before income taxes | 7 | (5) | 33 | 21 |
Income tax expenses | (10) | - | (24) | (13) |
Profit (loss) for the period | (4) | (5) | 9 | 8 |
Profit (loss) attributable to: | ||||
Owners of the Company | (5) | (5) | 6 | 4 |
Non-controlling interests | 1 | 1 | 3 | 4 |
Results from operating activities | 18 | 6 | 64 | 53 |
Restructuring and non-recurring items | (7) | (15) | (22) | (28) |
Adjusted EBIT | 24 | 21 | 86 | 81 |
Earnings per share (Euro) | (0.03) | (0.04) | 0.04 | 0.02 |
The Group has initially applied IFRS 16 at January 1, 2019, using the modified retrospective approach. Under this approach, comparative information is not restated. There has been no impact to retained earnings of initially applying IFRS 16 at the date of initial application.
Consolidated Statements of Comprehensive Income for the nine months ending September 2018 / September 2019 (in million Euro)
Unaudited, consolidated figures following IFRS accounting policies
9M 2019 | 9M 2018 | |
Profit / (loss) for the period | 9 | 8 |
Other Comprehensive Income, net of tax | ||
Items that are or may be reclassified subsequently to profit or loss: | ||
Exchange differences: | 17 | (1) |
Exchange differences on translation of foreign operations | 17 | (1) |
Cash flow hedges: | 4 | (14) |
Effective portion of changes in fair value of cash flow hedges | (9) | (8) |
Changes in the fair value of cash flow hedges reclassified to profit or loss | 3 | (5) |
Adjustments for amounts transferred to initial carrying amount of hedged items | 11 | (5) |
Income taxes | - | 4 |
Items that will not be reclassified subsequently to profit or loss: | - | (2) |
Equity investments at fair value through OCI – change in fair value | - | (1) |
Remeasurements of the net defined benefit liability | - | - |
Income tax on remeasurements of the net defined benefit liability | - | (1) |
Total other Comprehensive Income for the period, net of tax | 20 | (17) |
Total Comprehensive Income for the period attributable to: | 29 | (9) |
Owners of the Company | 26 | (13) |
Non-controlling interests | 3 | 4 |
Consolidated Statements of Comprehensive Income for the quarter ending September 2018 / September 2019 (in million Euro)
Unaudited, consolidated figures following IFRS accounting policies
Q3 2019 | Q3 2018 | |
Profit / (loss) for the period | (4) | (5) |
Other Comprehensive Income, net of tax | ||
Items that are or may be reclassified subsequently to profit or loss: | ||
Exchange differences: | 10 | - |
Exchange differences on translation of foreign operations | 10 | - |
Cash flow hedges: | (1) | (3) |
Effective portion of changes in fair value of cash flow hedges | (5) | (3) |
Changes in the fair value of cash flow hedges reclassified to profit or loss | 1 | - |
Adjustments for amounts transferred to initial carrying amount of hedged items | 4 | - |
Income taxes | - | - |
Items that will not be reclassified subsequently to profit or loss: | (1) | - |
Equity investments at fair value through OCI – change in fair value | (1) | - |
Remeasurements of the net defined benefit liability | - | - |
Income tax on remeasurements of the net defined benefit liability | - | - |
Total other Comprehensive Income for the period, net of tax | 7 | (3) |
Total Comprehensive Income for the period attributable to: | 4 | (8) |
Owners of the Company | 2 | (8) |
Non-controlling interests | 2 | - |
Consolidated Statement of Financial Position (in million Euro)
Unaudited, consolidated figures following IFRS accounting policies.
|
30/09/2019 |
31/12/2018 |
Non-current assets | 1,147 | 1,019 |
Goodwill | 528 | 523 |
Intangible assets | 88 | 93 |
Property, plant & equipment | 167 | 174 |
Right-of-use assets | 112 | - |
Investments in associates | 4 | 4 |
Other financial assets | 8 | 9 |
Trade receivables | 21 | 16 |
Receivables under finance leases | 80 | 62 |
Other assets | 23 | 24 |
Deferred tax assets | 116 | 114 |
Current assets | 1,252 | 1,348 |
Inventories | 512 | 498 |
Trade receivables | 379 | 420 |
Contract assets | 120 | 105 |
Current income tax assets | 70 | 71 |
Other tax receivables | 19 | 25 |
Receivables under finance lease | 17 | 30 |
Other receivables | 11 | 14 |
Other assets | 30 | 34 |
Derivative financial instruments | 1 | 1 |
Cash and cash equivalents | 81 | 141 |
Non-current assets held for sale | 10 | 10 |
TOTAL ASSETS | 2,399 | 2,367 |
|
30/09/2019 |
31/12/2018 |
Total equity | 322 | 290 |
Equity attributable to owners of the company | 277 | 252 |
Share capital | 187 | 187 |
Share premium | 210 | 210 |
Retained earnings | 862 | 854 |
Other reserves | (90) | (93) |
Translation reserve | 4 | (9) |
Post-employment benefits: remeasurements of the net defined benefit liability | (897) | (897) |
Non-controlling interests | 45 | 38 |
Non-current liabilities | 1,328 | 1,336 |
Liabilities for post-employment and long-term termination benefit plans | 1,009 | 1,066 |
Other employee benefits | 14 | 13 |
Loans and borrowings | 276 | 219 |
Provisions | 5 | 9 |
Deferred tax liabilities | 21 | 22 |
Trade payables | - | 2 |
Contract liabilities | 1 | 3 |
Other non-current liabilities | 1 | 2 |
Current liabilities | 749 | 741 |
Loans and borrowings | 81 | 66 |
Provisions | 44 | 52 |
Trade payables | 227 | 217 |
Contract liabilities | 171 | 163 |
Current income tax liabilities | 47 | 47 |
Other tax liabilities | 20 | 27 |
Other payables | 13 | 17 |
Employee benefits | 131 | 134 |
Other current liabilities | 4 | 4 |
Derivative financial instruments | 10 | 13 |
TOTAL EQUITY AND LIABILITIES | 2,399 | 2,367 |
The Group has initially applied IFRS 16 at January 1, 2019, using the modified retrospective approach.
Under this approach, comparative information is not restated.
There has been no impact to retained earnings of initially applying IFRS 16 at the date of initial application.
Consolidated Statement of Cash Flows (in million Euro) Unaudited, consolidated figures following IFRS accounting policies.
9M 2019 |
9M 2018 |
Q3 2019 |
Q3 2018 | |
Profit (loss) for the period | 9 | 8 | (4) | (5) |
Income taxes | 24 | 13 | 10 | - |
Share of (profit)/loss of associates, net of tax | 1 | 1 | - | - |
Net finance costs | 31 | 31 | 11 | 11 |
Operating result | 64 | 52 | 18 | 6 |
Depreciation, amortization and impairment losses | 47 | 40 | 19 | 14 |
Depreciation, amortization IFRS 16 | 29 | - | 10 | - |
Impairment losses on right-of-use assets (*) | 4 | - | - | - |
Exchange results and changes in fair value of derivates | 5 | (4) | 2 | (5) |
Recycling of hedge reserve | 3 | (5) | - | (5) |
Government grants and subsidies | (8) | (12) | (2) | (6) |
(Gains)/losses on the sale of intangible assets and PP&E and remeasurement of leases | (6) | (4) | (6) | - |
Expenses for defined benefit plans & long-term termination benefits | 29 | 30 | 7 | 6 |
Accrued expenses for personnel commitments | 66 | 67 | 25 | 27 |
Write-downs/reversal of write-downs on inventories | 10 | 11 | 2 | 3 |
Impairments/reversal of impairments on receivables | 4 | 4 | 1 | 2 |
Additions/reversals of provisions | 12 | 15 | 4 | 9 |
Other non-cash expenses | 116 | 101 | 35 | 30 |
Change in inventories | (10) | (82) | 20 | (26) |
Change in trade receivables | 37 | 15 | 11 | (18) |
Change in contract assets | (13) | (17) | - | (1) |
Change in trade working capital assets | 14 | (84) | 31 | (45) |
Change in trade payables | 13 | 21 | 7 | 17 |
Change in contract liabilities | 3 | 29 | (15) | 6 |
Changes in trade working capital liabilities | 15 | 50 | (9) | 23 |
Changes in trade working capital | 29 | (34) | 23 | (22) |
Cash out for employee benefits | (175) | (155) | (38) | (53) |
Cash out for provisions | (26) | (19) | (8) | (4) |
Changes in lease portfolio | (5) | (10) | (6) | (1) |
Changes in other working capital | - | 5 | 7 | 6 |
Cash settled operating derivatives | (12) | 16 | (4) | 16 |
Cash generated from operating activities | 70 | (3) | 55 | (8) |
Income taxes paid | (14) | (16) | (5) | (6) |
Net cash from / (used in) operating activities | 56 | (19) | 50 | (14) |
Capital expenditure | (26) | (31) | (9) | (10) |
Proceeds from sale of intangible assets and PP&E | 11 | 9 | 8 | 2 |
Acquisition of subsidiaries, net of cash acquired | (14) | (20) | (4) | (7) |
Interests received | 2 | 2 | 1 | 1 |
Dividends received | - | - | - | - |
Net cash from / (used in) investing activities | (27) | (41) | (4) | (14) |
9M 2019 |
9M 2018 |
Q3 2019 |
Q3 2018 | |
Interests paid | (11) | (10) | (2) | (4) |
Dividends paid to non-controlling interests | - | (3) | - | (3) |
Interests and dividends paid | (11) | (13) | (2) | (7) |
Proceeds from borrowings | 104 | 133 | 4 | 70 |
Repayment of borrowings | (150) | (34) | (41) | (27) |
Payment of finance leases | (32) | - | (12) | - |
Changes in borrowings | (79) | 99 | (48) | 43 |
Proceeds / (payment) of derivatives | 3 | (1) | 3 | (8) |
Other financing income / (costs) incurred | (3) | (2) | (1) | (1) |
Net cash from/ used in financing activities | (90) | 82 | (48) | 28 |
Net increase / (decrease) in cash & cash equivalents | (61) | 23 | (2) | - |
Cash & cash equivalents at the start of the period | 136 | 67 | 76 | 87 |
Net increase / (decrease) in cash & cash equivalents | (61) | 23 | (2) | - |
Effect of exchange rate fluctuations on cash held | (4) | (5) | (3) | (1) |
Cash & cash equivalents at the end of the period (**) | 72 | 85 | 72 | 85 |
The Group has initially applied IFRS 16 at January 1, 2019, using the modified retrospective approach.
Under this approach, comparative information is not restated.
(*) Partially offset by 3 million Euro reversal of provision for onerous rent.
(**) Bank overdrafts are presented in minus of cash and cash equivalents in the cash flow statement: September 2019 9 million Euro, September 2018 10 million Euro.
Consolidated Statement of changes in Equity (in million Euro)
Unaudited, consolidated figures following IFRS accounting policies.
Attachments
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Agfa-Gevaert N.V.mehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Agfa-Gevaert N.V.mehr Analysen
Aktien in diesem Artikel
Agfa-Gevaert N.V. | 0,72 | 2,72% |